Effects of pharmaceutical care interventions on blood pressure and medication adherence of patients with primary hypertension in China

The objective of this study was to assess the effects of pharmaceutical care interventions on blood pressure (BP) and medication adherence of patients with primary hypertension in China. A total of 60 patients with primary hypertension were enrolled in the trial for a 12-month period. Participants were randomized to either control group or intervention group in a 1:1 ratio. During the follow-up period, patients in the control group were given regular medi-care, while patients in the intervention group accepted pharmaceutical care. The dates of baseline demographics, medication lists, measurement of medication adherence, and BP values were collected. Statistical analyses were conducted using t-test or χ2 test. After 12 months follow-up, 24-h BP was significantly decreased by 9.75 mmHg (7.1%) for systolic blood pressure (SBP) and 5.88 mmHg (6.6%) for diastolic blood pressure (DBP) in the intervention group (p < 0.05) compared with their initial visit, while there was no significant change in the control group (p > 0.05). The intervention group demonstrated a higher percentage of patients with high adherence (72.41%) at 12 months, whereas the control group hardly had changes in medication compliance. In conclusion, the results indicate that pharmaceutical care intervention might contribute to better BP control of primary hypertension, and could enhance medication compliance of patients.